Last reviewed · How we verify

Sumatriptan Succinate Oral Tablet — Competitive Intelligence Brief

Sumatriptan Succinate Oral Tablet (Sumatriptan Succinate Oral Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triptan (5-HT1B/1D receptor agonist). Area: Neurology.

marketed Triptan (5-HT1B/1D receptor agonist) 5-HT1B receptor, 5-HT1D receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Sumatriptan Succinate Oral Tablet (Sumatriptan Succinate Oral Tablet) — Damanhour Teaching Hospital. Sumatriptan selectively binds to serotonin 5-HT1B/1D receptors on cranial blood vessels and nerve terminals, causing vasoconstriction and inhibiting neuropeptide release to relieve migraine headaches.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sumatriptan Succinate Oral Tablet TARGET Sumatriptan Succinate Oral Tablet Damanhour Teaching Hospital marketed Triptan (5-HT1B/1D receptor agonist) 5-HT1B receptor, 5-HT1D receptor
Migranal nasal spray at 4 hour Migranal nasal spray at 4 hour Thomas Jefferson University marketed Ergot alkaloid; 5-HT1B/1D receptor agonist 5-HT1B receptor, 5-HT1D receptor
Migranal nasal spray at 1 hour Migranal nasal spray at 1 hour Thomas Jefferson University marketed Ergot alkaloid; serotonin receptor agonist 5-HT1B receptor, 5-HT1D receptor
naratriptan HCl naratriptan HCl Cady, Roger, M.D. marketed Triptan (5-HT1B/1D receptor agonist) 5-HT1B receptor, 5-HT1D receptor
sumatriptan succinate/naproxen sodium sumatriptan succinate/naproxen sodium GlaxoSmithKline marketed 5-HT1B/1D receptor agonist combined with NSAID 5-HT1B receptor, 5-HT1D receptor, COX-1, COX-2
NP101 - Sumatriptan iontophoretic transdermal patch NP101 - Sumatriptan iontophoretic transdermal patch NuPathe Inc. phase 3 5-HT1B/1D receptor agonist (triptan) 5-HT1B receptor, 5-HT1D receptor
AXS-07 AXS-07 Axsome Therapeutics, Inc. phase 3 Triptan combination / 5-HT1B/1D receptor agonist 5-HT1B receptor, 5-HT1D receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triptan (5-HT1B/1D receptor agonist) class)

  1. Organon and Co · 3 drugs in this class
  2. Cady, Roger, M.D. · 1 drug in this class
  3. Damanhour Teaching Hospital · 1 drug in this class
  4. Merck Sharp & Dohme LLC · 1 drug in this class
  5. Teva Pharmaceuticals USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sumatriptan Succinate Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/sumatriptan-succinate-oral-tablet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: